Professional
Added to YB: 2026-02-12
Pitch date: 2026-02-04
BNTX [bullish]
BioNTech SE
-14.89%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
Market Cap
$17.9B
Pitch Price
$107.25
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.06
P/E
-15.84
EV/Sales
1.53
Sector
Biotechnology
Category
value
Show full summary:
LMN Capital Added On Portfolio Holding: BioNTech SE
BNTX (added to position): $19B net cash (83% of $23B mkt cap), COVID vaccine biz generating low single-digit $B revs w/ 50%+ pre-tax margin. 25+ clinical programs; sold 50% BNT327 rights to BMY for $3.5B + $7.5B milestones after $1B acquisition. Down 15% in 2025 on US vaccine headwinds despite pipeline progress.
Read full article (2 min)